Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy

Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cytocom, Inc., a biopharmaceutical company creating next-gen immune therapies, received clearance from the U.S. FDA for its IND application for a Phase 2 trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2, the virus that causes COVID-19. CYTO-205 is designed to modulate immune system function, decrease elevated inflammatory responses associated with viral infection and inhibit viral replication in human lung cells.
 
The trial will evaluate safety and efficacy of CYTO-205 in adult patients with mild COVID-19 infection who are at high risk for disease progression. Patient enrollment will begin during the 2Q21 at Loma Linda University Health in Loma Linda, CA.
 
“Even as new vaccines are introduced into the market and inoculation programs continue to expand, the need for safe and effective therapies to treat COVID-19 remains undiminished, especially in light of the spread of new, highly contagious variants of the virus,” stated Michael Handley, President & CEO of Cytocom. “The early data regarding the potential of CYTO-205, as both an interventional therapy and a preventative agent is compelling, and we look forward to working with investigators at Loma Linda to further explore the possibilities.”
 
Preclinical in vitro studies using coronavirus strain 229E and the pathological corona virus strain, SARS-CoV-2, have demonstrated the potential of CYTO-205 to inhibit the replication of corona viruses in human lung cells. Previously generated data also suggest that CYTO-205 could prevent the life-threatening lung inflammation caused by COVID-19, as well as lessen the risk of reinfection.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics